Drug Therapy
Development
AP-001
A New Era in Cancer Treatment
Our Therapeutics

Pre-Clinical Results | Trials

Pancreatic Cancer
Current treatments primarily involve chemotherapy and radiation therapy, aiming to control the disease and improve patient quality of life.

Cancer Globally

Annually

Each Year


in the U.S.

Tumor Removal
Less Than 20%
Ovarian Cancer
Five-year ovarian cancer survival rates vary between countries. For example, in more developed countries, current rates range from 36% to 46%. However, in some countries, the figure is much lower.
The five-year survival rate is 51%, falling well below that for other cancers.
The first-line treatment for ovarian cancer typically includes surgery, followed by chemotherapy with platinum-based agents and a taxane.


Annually

Each Year


51% Five-Year
Survival Rate
Source: World Ovarian Cancer Coalition
Promising Advancements
in Pancreatic Cancer Treatment
Avenzoar’s leading investigational drug, AP-001, represents a promising advancement in pancreatic cancer treatment. Through rigorous preclinical studies, AP-001 has shown potential in inhibiting metastasis and overcoming chemo-resistance mechanisms, critical challenges in treating pancreatic cancer. As Avenzoar prepares for clinical trials in 2025, our focus on developing breakthrough therapies underscores a commitment to improving patient outcomes and transforming cancer care.
In summary, pancreatic cancer poses a significant public health challenge worldwide, characterized by high mortality rates, limited treatment options, and a pressing need for continued research and clinical advancements to improve patient outcomes.

Dr. Stephen Pandol
Director of Basic and Translational
Pancreas Research at Cedars-Sinai Medical Center
Our rigorous clinical development program is designed to meet the highest standards of regulatory scrutiny.
Avenzoar Pharmaceuticals is working closely with regulatory bodies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to ensure that AP-001 meets all regulatory requirements for approval.

We are actively seeking collaboration opportunities with major pharmaceutical companies to bring AP-001 to patients. Engaging with industry leaders will enable us to leverage their manufacturing, distribution, and training capabilities to ensure that AP-001 reaches the pancreatic cancer patients who need it most.